Imagine trying to design a single material that must shine brightly enough to see deep inside the body, generate enough heat and chemical energy to destroy tumors, and remain stable long enough to reach its target—all without compromising one another. This is the tripartite trade-off that has long frustrated researchers developing phototheranostic agents for cancer.
Now, a team of scientists from Shenzhen University has found an elegant solution: replace ordinary hydrogen atoms with deuterium, a heavier, non-radioactive isotope. The result, published in Science Bulletin, is a “deuterium engineering” strategy that tackles all three challenges at once through a triple-action mechanism.
“Deuterium substitution acts like a molecular shock absorber,” explains Prof. Wang, corresponding author of the study. “It suppresses high-frequency vibrations that waste energy, promotes tighter molecular packing, and increases the hydrophobicity of the nanoparticles—three effects that work together to enhance imaging, therapy, and stability simultaneously.”
The team synthesized a series of deuterated derivatives (TTBT-d10, d20, and d28) based on an aggregation-induced emission luminogen (AIEgen) called TTBT. The fully deuterated version, TTBT-d28, showed a 25.9% increase in fluorescence quantum yield, a 14.2% rise in reactive oxygen species generation, and a 20.7% improvement in plasma stability compared to the non-deuterated version.
In orthotopic breast cancer models, a single injection of TTBT-d28 nanoparticles followed by a brief laser irradiation completely eradicated tumors with no recurrence over 15 days. Comprehensive biosafety assessments confirmed no observable toxicity to major organs or blood parameters.
Perhaps most importantly, the enhanced fluorescence brightness translated directly into clinical utility. In a colorectal cancer model, the nanoparticles enabled high-contrast vascular imaging with 25% better spatial resolution and 31% higher signal-to-background ratio than the non-deuterated counterpart. During fluorescence-guided surgery, the real-time NIR-II imaging revealed residual tumor tissue that was invisible under white light — allowing surgeons to perform a second, targeted resection that completely cleared all remaining cancer cells. Untreated mice reached humane endpoints within 20 days, while those that received the fluorescence-guided surgery survived beyond 60 days.
“This work demonstrates that deuteration is not just a photophysical curiosity — it delivers tangible clinical benefits,” says Prof. Wang. “The strategy does not require redesigning the molecular backbone, so it can be readily applied to upgrade existing phototheranostic systems. We believe this will become a routine tool in the development of next-generation precision oncology platforms.”
Science Bulletin
Experimental study